Allogeneic transplantation in multiple myeloma

Haematologica

Volumn 93, Issue 9, 2008, Pages 1295-1300

  Gahrton, Gösta ^a   Björkstrand, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; REVIEW;

ANTILYMPHOCYTE SERUM; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 50849106088     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13555     Document Type: Review

References (27)

1. Gahrton G, Ringden O, Lonnqvist B, Lindquist R, Ljungman P. Bone marrow transplantation in three patients with multiple myeloma. Acta Med Scand 1986;219:523-7.
2. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991;325:1267-73.
3. Björkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-8.
4. Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant 2005;35:609-17.
5. Hambach L, Spierings E, Goulmy E. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract Res Clin Haematol 2007;20:171-87.
6. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-16.
7. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17:208-15.
8. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-9.
9. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
10. Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423-32.
11. Kröger N, Shimoni A, Nagler A, et al. Current status and perspectives of dose-reduced conditioning followed by related and unrelated stem cell transplantation. Haematologica 2005;90:47.
12. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-94.
13. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80.
14. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-20.
15. Bladé J, Rosinol L, Pérez-Simon J, Sureda A, De La Rubia J, De Arriba F, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced - intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma [abstract]. Haematologica 2008;93(s1):166.
16. Lokhorst H, Mutis I. Allogeneic transplantation and immune interventions in multiple myeloma. In: Green T, Salles G, Boregaard N, eds. Hematology Education: the education programme for the annual congress of the European Hematology Association 2008; 2:106-14.
17. Björkstrand B, Iacobelli S, Hegenbart U, et al. Autologous stem cell transplantation (ASCT) versus ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT. Bone Marrow Transplant 2008;41:S38.
18. Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005;129:631-43.
19. van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135-41.
20. Ayuk F, Perez-Simon J, Shimoni A, Shimoni A, Sureda A, Zabelina T, et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 2008;93:1343-50.
21. Remberger M, Mattsson J, Svahn B, Ringdén O. Using reduced intensity conditioning and HLA-identcal sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose. Submitted for publication 2008.
22. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004;101:8120-5.
23. Mateos-Mazon J, Perez-Simon JA, Lopez O, Hernandez E, Etxebarria J, San Miguel JF. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica 2007;92:1295-6.
24. Lokhorst H. Allogeneic transplantation in multiple myeloma. Haematologica 2007;92:52-4.
25. Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008;111:3155-62.
26. Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, Dilber MS. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol 2007;35:1839-46.
27. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.